| Status | In progress |
| Decision | Selected |
| Process | STA Review |
| ID number | 3778 |
Provisional Schedule
| Final draft guidance | 06 May 2022 - 19 May 2022 |
| Expected publication | 08 June 2022 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TAteam1@nice.org.uk
| External Assessment Group | School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors | Janssen |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Lymphoma Action |
| WMUK | |
| Professional groups | Association of Cancer Physicians |
| British Society for Haematology | |
| Cancer Research UK | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Comparator companies | Janssen-Cilag |
| General commentators | All Wales Therapeutic Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 January 2022 - 11 February 2022 | Draft guidance |
| 07 December 2021 | Committee meeting: 1 |
| 10 June 2021 | Invitation to participate |
| 19 March 2021 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual